论文部分内容阅读
目的:通过分析我院2007、2008年第二季度人血白蛋白的临床使用情况,分析其使用的合理性,了解国家对血液制品的监管所产生的影响。方法:对2007年4～6月和2008年4～6月所有使用白蛋白的住院患者进行回顾性调查,收集相关数据,统计分析。结果:2007年二季度有2267例患者使用17537瓶白蛋白,用药金额590.4万元,2008年同期有1565例患者使用9403瓶白蛋白,用药金额353.2万元,同期相比用药金额下降了67.15%;其中用量较大的主要是危重患者;个人用量分布,以使用10～20 g的患者最多,与2007年同期相比其比例上升了14.84%;对比美国适应证的标准,符合标准的比例由2007年18.57%上升到2008年同期的25.81%。结论:国家对血液制品的监管,对临床更加严格掌握白蛋白使用适应证、重视循证医学、节约成本等都有深远影响。
OBJECTIVE: To analyze the clinical use of human serum albumin in our hospital in the second quarter of 2007 and 2008, analyze the rationality of its use, and understand the impact of state regulation of blood products. Methods: A retrospective survey was conducted on all inpatients using albumin from April to June in 2007 and from April to June in 2008. Relevant data and statistical analysis were collected. Results: In the second quarter of 2007, there were 2267 patients with 17537 bottles of albumin and the medication amount was 5.9 million yuan. In the same period in 2008, 1565 patients used 9403 bottles of albumin and the medication amount was 3.532 million yuan, down by 67.15% over the same period. ; Among them, the dosage was mainly for critically ill patients; the personal dosage distribution was the most used in patients with 10-20 g, up 14.84% compared with that of the same period of 2007. Compared with the standard of US Indications, the proportion of compliance with the standard was 18.57% in 2007 rose to 25.81% over the same period in 2008. Conclusion: The state regulation of blood products has a far-reaching impact on the clinical application of more rigorous indications of albumin, evidence-based medicine, and cost-saving.